These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 12477049

  • 21. Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC).
    Kroep JR, van Moorsel CJ, Veerman G, Voorn DA, Schultz RM, Worzalla JF, Tanzer LR, Merriman RL, Pinedo HM, Peters GJ.
    Adv Exp Med Biol; 1998; 431():657-60. PubMed ID: 9598147
    [No Abstract] [Full Text] [Related]

  • 22. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
    Bergman AM, Pinedo HM, Jongsma AP, Brouwer M, Ruiz van Haperen VW, Veerman G, Leyva A, Eriksson S, Peters GJ.
    Biochem Pharmacol; 1999 Feb 15; 57(4):397-406. PubMed ID: 9933028
    [Abstract] [Full Text] [Related]

  • 23. Quantitative real time PCR of deoxycytidine kinase mRNA by Light Cycler PCR; in relation to enzyme activity.
    Sigmond J, Loves WJ, Kroep JR, Peters GJ.
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct 15; 23(8-9):1347-50. PubMed ID: 15571256
    [Abstract] [Full Text] [Related]

  • 24. Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.
    Ruiz van Haperen VW, Veerman G, Eriksson S, Boven E, Stegmann AP, Hermsen M, Vermorken JB, Pinedo HM, Peters GJ.
    Cancer Res; 1994 Aug 01; 54(15):4138-43. PubMed ID: 8033147
    [Abstract] [Full Text] [Related]

  • 25. Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
    Funamizu N, Okamoto A, Kamata Y, Misawa T, Uwagawa T, Gocho T, Yanaga K, Manome Y.
    Oncol Rep; 2010 Feb 01; 23(2):471-5. PubMed ID: 20043109
    [Abstract] [Full Text] [Related]

  • 26. Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells.
    Hodzic J, Giovannetti E, Diosdado B, Adema AD, Peters GJ.
    Nucleosides Nucleotides Nucleic Acids; 2011 Dec 01; 30(12):1214-22. PubMed ID: 22132977
    [Abstract] [Full Text] [Related]

  • 27. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.
    Bergman AM, Eijk PP, Ruiz van Haperen VW, Smid K, Veerman G, Hubeek I, van den Ijssel P, Ylstra B, Peters GJ.
    Cancer Res; 2005 Oct 15; 65(20):9510-6. PubMed ID: 16230416
    [Abstract] [Full Text] [Related]

  • 28. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.
    Réjiba S, Bigand C, Parmentier C, Hajri A.
    Neoplasia; 2009 Jul 15; 11(7):637-50. PubMed ID: 19568409
    [Abstract] [Full Text] [Related]

  • 29. Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro.
    Grégoire V, Rosier JF, De Bast M, Bruniaux M, De Coster B, Octave-Prignot M, Scalliet P.
    Radiother Oncol; 2002 Jun 15; 63(3):329-38. PubMed ID: 12142097
    [Abstract] [Full Text] [Related]

  • 30. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
    Sugiyama E, Kaniwa N, Kim SR, Hasegawa R, Saito Y, Ueno H, Okusaka T, Ikeda M, Morizane C, Kondo S, Yamamoto N, Tamura T, Furuse J, Ishii H, Yoshida T, Saijo N, Sawada J.
    Clin Pharmacokinet; 2010 Aug 15; 49(8):549-58. PubMed ID: 20608756
    [Abstract] [Full Text] [Related]

  • 31. Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver.
    van der Wilt CL, Kroep JR, Loves WJ, Rots MG, Van Groeningen CJ, Kaspers GJ, Peters GJ.
    Eur J Cancer; 2003 Mar 15; 39(5):691-7. PubMed ID: 12628850
    [Abstract] [Full Text] [Related]

  • 32. Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene.
    Beauséjour CM, Gagnon J, Primeau M, Momparler RL.
    Biochem Biophys Res Commun; 2002 May 24; 293(5):1478-84. PubMed ID: 12054682
    [Abstract] [Full Text] [Related]

  • 33. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
    Gourdeau H, Clarke ML, Ouellet F, Mowles D, Selner M, Richard A, Lee N, Mackey JR, Young JD, Jolivet J, Lafrenière RG, Cass CE.
    Cancer Res; 2001 Oct 01; 61(19):7217-24. PubMed ID: 11585758
    [Abstract] [Full Text] [Related]

  • 34. Human equilibrative nucleoside transporter-1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma.
    Attia F, Fathy S, Anani M, Hassan A, Attia F, Ibrahim G, Elazab M.
    J Clin Lab Anal; 2020 Nov 01; 34(11):e23457. PubMed ID: 32671914
    [Abstract] [Full Text] [Related]

  • 35. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM, Munch-Petersen B, Jensen PB, Sehested M, Veerman G, Voorn DA, Smid K, Pinedo HM, Peters GJ.
    Biochem Pharmacol; 2001 Jun 01; 61(11):1401-8. PubMed ID: 11331076
    [Abstract] [Full Text] [Related]

  • 36. dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study.
    Xiong J, Altaf K, Ke N, Wang Y, Tang J, Tan C, Li A, Zhang H, He D, Liu X.
    Medicine (Baltimore); 2016 Mar 01; 95(10):e2936. PubMed ID: 26962792
    [Abstract] [Full Text] [Related]

  • 37. Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene.
    Galmarini CM, Clarke ML, Jordheim L, Santos CL, Cros E, Mackey JR, Dumontet C.
    BMC Pharmacol; 2004 May 24; 4():8. PubMed ID: 15157282
    [Abstract] [Full Text] [Related]

  • 38. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.
    McAllister F, Pineda DM, Jimbo M, Lal S, Burkhart RA, Moughan J, Winter KA, Abdelmohsen K, Gorospe M, Acosta Ade J, Lankapalli RH, Winter JM, Yeo CJ, Witkiewicz AK, Iacobuzio-Donahue CA, Laheru D, Brody JR.
    Cancer Biol Ther; 2014 Jun 01; 15(6):688-98. PubMed ID: 24618665
    [Abstract] [Full Text] [Related]

  • 39. Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer.
    Ashida R, Nakata B, Shigekawa M, Mizuno N, Sawaki A, Hirakawa K, Arakawa T, Yamao K.
    J Exp Clin Cancer Res; 2009 Jun 16; 28(1):83. PubMed ID: 19531250
    [Abstract] [Full Text] [Related]

  • 40. Adenoviral vector transduction of the human deoxycytidine kinase gene enhances the cytotoxic and radiosensitizing effect of gemcitabine on experimental gliomas.
    Szatmári T, Huszty G, Désaknai S, Spasokoukotskaja T, Sasvári-Székely M, Staub M, Esik O, Sáfrány G, Lumniczky K.
    Cancer Gene Ther; 2008 Mar 16; 15(3):154-64. PubMed ID: 18188186
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.